nach oben

Drugs

Erschienen in:

01.12.2010 | Review Article

Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus

verfasst von: Taina K. Mattila, Professor Anthonius de Boer

Erschienen in: Drugs | Ausgabe 17/2010

Einloggen, um Zugang zu erhalten

Abstract

In type 1 and 2 diabetes mellitus patients, hyperglycaemia is independently related to the development of microvascular and macrovascular complications. Glycaemic targets and the benefits of intensive versus conventional glucose control are under debate. The purpose of this review is to provide an overview of the randomized controlled trials and meta-analyses comparing the effects of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes.

MEDLINE and Cochrane database searches were performed with a limit on randomized controlled trials or meta-analysis and keywords related to glucose control and diabetes. In addition, related articles and reference lists of relevant articles and guidelines were reviewed.

Nine randomized controlled trials, three in type 1 and six in type 2 diabetes, and four meta-analyses in type 2 diabetes were reviewed. These studies included more than 30 000 patients. On the basis of these trials and metaanalyses, it can be concluded that intensive glucose control has a beneficial effect on microvascular complications (retinopathy, nephropathy, neuropathy) in both type 1 and type 2 diabetes patients. The risk reduction of developing a microvascular complication varied between 25% and 76%. Particularly in patients with type 2 diabetes, there was a 10–15% decrease in nonfatal myocardial infarction with intensive glucose control, but no effect on stroke, cardiovascular death or all-cause mortality was observed. There was a beneficial effect of intensive glucose control on cardiovascular disease in patients with type 1 diabetes in only one trial. In all studies, intensive glucose control was associated with at least twice the risk for serious hypoglycaemia than the conventional-control group.

In conclusion, compared with conventional glucose control, intensive glucose control is associated with fewer microvascular complications in both type 1 and type 2 diabetes, a decrease in coronary events, especially in type 2 diabetes, and more serious hypoglycaemia.

WHO. Diabetes Action Now: an initiative of the World Health Organization and the International Diabetes Federation. Geneva: WHO, 2004

Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 77–82CrossRef

The A.D.A.M. medical encyclopedia [online]. Available from URL: http://www.nlm.nih.gov/medlineplus/encyclopedia.html [Accessed 2010 Aug 25]

Laakso M. Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937–42PubMedCrossRef

Gerstein HC, Pogue J, Mann JFE, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749–55PubMedCrossRef

Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A_1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413–20PubMed

Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated haemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–31PubMed

Stettler C, Alleman S, Jüni P, et al. Glycemic control and macrovascular disease in type 1 and 2 diabetes mellitus: meta-analysis of randomized studies. Am Heart J 2006; 152: 27–38PubMedCrossRef

Fox CS, Coacy S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115: 1544–50PubMedCrossRef

10.

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86CrossRef

11.

Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304–9PubMedCrossRef

12.

Microalbuminuria Collaborative Study Group. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311: 973–7CrossRef

13.

Lasker RD. The Diabetes Control and Complications Trial: implications for policy and practice. N Engl J Med 1993; 329: 1035–6PubMedCrossRef

14.

The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342(6): 381–9CrossRef

15.

The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643–53CrossRef

16.

Chaturvedi N, Fuller JH. Effect of intensive treatment in insulin dependent diabetes mellitus with microalbuminuria: sample size was too small [letter]. BMJ 1996; 312: 253–4PubMedCrossRef

17.

Bender R, Sawicki PT. Effect of intensive treatment in insulin dependent diabetes mellitus with microalbuminuria: interpretation of study’s results is open to criticism [letter]. BMJ 1996; 312: 254PubMedCrossRef

18.

Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17PubMedCrossRef

19.

UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53CrossRef

20.

UK Prospective Diabetes Study Group. Intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854–65CrossRef

21.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59CrossRef

22.

The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72CrossRef

23.

Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 160: 129–39CrossRef

24.

Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998; 352: 832–3PubMedCrossRef

25.

UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) VIII: study design, progress and performance. Diabetologia 1991; 34: 877–90CrossRef

26.

Ismail-Beigi F, Craven T, Banerij MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet 2010; 376: 419–30PubMedCrossRef

27.

American Diabetes Association. Standards of medical care in diabetes — 2009. Diabetes Care 2009; 32 Suppl. 1: S13–61CrossRef

28.

Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358: 2630–3PubMedCrossRef

29.

Rosen CJ. Revisiting the rosiglitazone story: lessons learned. N Engl J Med 2010; 363: 803–6PubMedCrossRef

30.

Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33(7): 1578–84PubMedCrossRef

31.

Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33(5): 983–90PubMedCrossRef

32.

Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33(4): 721–7PubMedCrossRef

33.

Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2009; 339: b4909

34.

Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2009; 339: b5444CrossRef

35.

Banarer S. Glucose control and vascular complications in type 2 diabetes [letter]. N Engl J Med 2009; 360: 2031PubMedCrossRef

36.

Luan FL. Glucose control and vascular complications in type 2 diabetes. N Engl J Med 2009; 360: 2031–2PubMedCrossRef

37.

Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373(9677): 1765–72PubMedCrossRef

38.

Ma J, Yang W, Fang N, et al. The association between intensive glycemic control and vascular complications in type 2 diabetes patients. Nutr Metab Cardiovasc Dis 2009; 19(9): 596–603PubMedCrossRef

39.

Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151(6): 394–403PubMed

40.

Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–98PubMedCrossRef

41.

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitA-zone Clinical Trial In macro Vascular Events): a randomized controlled trial. Lancet 2005; 366(9492): 1279–89PubMedCrossRef

42.

Abraira C, Colwell J, Nuttal F, et al. Cardiovascular events and correlates in the veterans affairs diabetes feasibility trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997; 157(2): 181–8PubMedCrossRef

43.

Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 383–93PubMedCrossRef

44.

Chaggar PS, Shaw SM, Williams SG. Review article: thiazolidinediones and heart failure. Diab Vasc Dis Res 2009; 6: 146–52PubMedCrossRef

45.

Akalin S, Berntorp K, Ceriello A, et al. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract 2009; 63(10): 1421–5PubMedCrossRef

46.

Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010; 7(7): 369–75PubMedCrossRef

Titel: Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus
verfasst von: Taina K. Mattila
Professor Anthonius de Boer
Publikationsdatum: 01.12.2010
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 17/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11585220-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17/2010

Triple-Negative Breast Cancer

Fentanyl Sublingual

Olanzapine Long-Acting Injection

Indacaterol

Trastuzumab

Drugs in Development for Tuberculosis